Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HINT1 | P49773 | 3/20 | 0.52 |
| ▸ | HPGD | P15428 | 2/20 | 0.51 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.51 |
| ▸ | NT5E | P21589 | 1/20 | 0.49 |
| ▸ | STING1 | Q86WV6 | 2/20 | 0.48 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.48 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.48 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.48 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.47 |
| ▸ | GSK3A | P49840 | 2/20 | 0.47 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.47 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12151803 | 1.00 | HINT1 (0.52) | HINT1HPGDADORA3NT5ESTING1 | |
| SCHEMBL1374868 | 1.00 | HINT1 (0.52) | HINT1HPGDADORA3NT5ESTING1 | |
| SCHEMBL7101375 | 0.89 | ADORA3 (0.53) | HINT1HPGDADORA3NT5ESTING1 | |
| SCHEMBL29908542 | 0.88 | ADORA3 (0.52) | HINT1HPGDADORA3NT5ESTING1 | |
| SCHEMBL28911222 | 0.88 | HPGD (0.54) | HINT1HPGDADORA3NT5ESTING1 | |
| SCHEMBL3734057 | 0.88 | ADORA3 (0.51) | HINT1HPGDADORA3NT5ESTING1 | |
| SCHEMBL29771263 | 0.87 | HINT1 (0.51) | HINT1HPGDADORA3NT5ESTING1 | |
| SCHEMBL3427138 | 0.87 | ADORA3 (0.50) | HINT1HPGDADORA3NT5ESTING1 | |
| SCHEMBL18490626 | 0.86 | ADORA3 (0.52) | HINT1HPGDADORA3NT5ESTING1 | |
| SCHEMBL5950284 | 0.86 | HPGD (0.47) | HINT1HPGDADORA3NT5EADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9249173-B2 | Compounds and pharmaceutical compositions for the treatment of viral infections | IDENIX PHARMACEUTICALS, LLC (US) | 2016-02-02 | — | — | US | disclosed |
| US-20140255339-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VIRAL INFECTIONS | IDENIX PHARMACEUTICALS, INC. (US) | 2014-09-11 | — | — | US | disclosed |
| US-20110286962-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VIRAL INFECTIONS | IDENIX PHARMACEUTICALS, INC. | 2011-11-24 | — | — | US | disclosed |
| US-7951789-B2 | Compounds and pharmaceutical compositions for the treatment of viral infections | IDENIX PHARMACEUTICALS, INC. (US) | 2011-05-31 | — | — | US | disclosed |
| US-7902202-B2 | Compounds and pharmaceutical compositions for the treatment of viral infections | IDENIX PHARMACEUTICALS, INC. (US) | 2011-03-08 | — | — | US | disclosed |
| US-20090169504-A1 | Compounds and Pharmaceutical compositions for the treatment of Viral infections | IDENIX PHARMACEUTICALS, INC | 2009-07-02 | — | — | US | disclosed |
| US-20080286230-A1 | Compounds and pharmaceutical compositions for the treatment of viral infections | IDENIX PHARMACEUTICALS, INC. | 2008-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090169504-A1 | Compounds and Pharmaceutical compositions for the treatment of Viral infections | HAVCR2, PYGL, GYS2 | HINT1 337/4885HPGD 403/4885ADORA3 1822/4885 |
| US-20080286230-A1 | Compounds and pharmaceutical compositions for the treatment of viral infections | HAVCR2, PYGL, GYS2 | HINT1 337/4885HPGD 403/4885ADORA3 1822/4885 |
| US-20140255339-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VIRAL INFECTIONS | HAVCR2, PYGL, GYS2 | HINT1 337/4885HPGD 403/4885ADORA3 1822/4885 |
| US-20110286962-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VIRAL INFECTIONS | HAVCR2, PYGL, GYS2 | HINT1 337/4885HPGD 403/4885ADORA3 1822/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.